Evidence map›Paper›PMID 35629938›Full record

ArticleMetabolites2022

Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability.

Mia J Coleman, Luis M Espino, Hernan Lebensohn, Marija V Zimkute, Negar Yaghooti, Christina L Ling, Jessica M Gross, Natalia Listwan, Sandra Cano, Vanessa Garcia and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Colonic metabolomic and transcriptomic alterations in a mouse model of metabolic syndrome.American journal of physiology. Gastrointestinal and liver physiology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Proteomics and Metabolomics in Biomedicine.International journal of molecular sciences · 2023
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Mia J ColemanUniversity of New Mexico School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Luis M EspinoUniversity of New Mexico School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Hernan LebensohnUniversity of New Mexico School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.ORCID 0000-0003-3067-640X
Marija V ZimkuteClinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Negar YaghootiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Christina L LingDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Jessica M GrossClinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.ORCID 0000-0002-5221-8218
Natalia ListwanClinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Sandra CanoClinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Vanessa GarciaClinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Debbie M LovatoClinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Susan L TigertClinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Drew R JonesMetabolomics Core Resource Laboratory, New York University Langone Health, New York, NY 10016, USA.ORCID 0000-0001-8732-9818
Rama R GullapalliDepartment of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Neal E RakovDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Euriko G Torrazza PerezDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Eliseo F CastilloClinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.ORCID 0000-0002-5083-560X
University of New Mexico · USNYU Langone Health · US

Funding

UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
NCATS NIH HHS UL1 TR001449NCATS NIH HHS UL1TR001449
6 · The paper itself

Abstract

backgroundMetabolic Syndrome (MetS) is a clinical diagnosis where patients exhibit three out of the five risk factors: hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, hyperglycemia, elevated blood pressure, or increased abdominal obesity. MetS arises due to dysregulated metabolic pathways that culminate with insulin resistance and put individuals at risk to develop various comorbidities with far-reaching medical consequences such as non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease. As it stands, the exact pathogenesis of MetS as well as the involvement of the gastrointestinal tract in MetS is not fully understood. Our study aimed to evaluate intestinal health in human subjects with MetS.

methodsWe examined MetS risk factors in individuals through body measurements and clinical and biochemical blood analysis. To evaluate intestinal health, gut inflammation was measured by fecal calprotectin, intestinal permeability through the lactulose-mannitol test, and utilized fecal metabolomics to examine alterations in the host-microbiota gut metabolism.

resultsNo signs of intestinal inflammation or increased intestinal permeability were observed in the MetS group compared to our control group. However, we found a significant increase in 417 lipid features of the gut lipidome in our MetS cohort. An identified fecal lipid, diacyl-glycerophosphocholine, showed a strong correlation with several MetS risk factors. Although our MetS cohort showed no signs of intestinal inflammation, they presented with increased levels of serum TNFα that also correlated with increasing triglyceride and fecal diacyl-glycerophosphocholine levels and decreasing HDL cholesterol levels.

conclusionTaken together, our main results show that MetS subjects showed major alterations in fecal lipid profiles suggesting alterations in the intestinal host-microbiota metabolism that may arise before concrete signs of gut inflammation or intestinal permeability become apparent. Lastly, we posit that fecal metabolomics could serve as a non-invasive, accurate screening method for both MetS and NAFLD.

Indexed as

dyslipidemialipidomicsmetabolic syndromemetabolomics

Identifiers

PMID35629938
PMCPMC9143200
OpenAlexW4280614806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.